Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues
Pliant Therapeutics halted new enrollment in its BEACON-IPF trial after a safety board review. A separate study showed ...
FierceBiotech22 小时
Pliant pauses phase 2 lung fibrosis trial on advice of safety committee
Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...
BBC9 个月
Bangladesh's burgeoning pharmaceuticals
One such exporter is Beacon Pharmaceuticals, founded in 2006, which became the first company in Bangladesh to export cancer drugs. “It was founder Mohammad Ebadul Karim’s vision to transform ...
来自MSN11 个月
'It's a hidden gem.' Beacon Charitable Pharmacy's new director working to raise profile
CANTON − Latrice Snodgrass, the new executive director of the Beacon Charitable Pharmacy, says one of her main goals is to make more people aware of the place she calls "a hidden gem." ...
The Pharma Letter19 小时
Pliant Thera sinks as it pauses trial
Pliant Therapeutics, a Californian biopharma focused on discovering and developing fibrosis drugs, saw its shares close down ...
GlobalData on MSN12 天
FDA gives RMAT designation to Beacon’s retinitis pigmentosa treatment
The FDA has granted RMAT designation to Beacon Therapeutics’ gene therapy, laru-zova, for treating X-linked retinitis ...
pharmaphorum1 天
Beacon lights up with $170m for retinal disease gene therapy
UK-headquartered Beacon Therapeutics has raised a whopping $170 million in second-round financing that will be used to advance a gene therapy for an inherited cause of blindness through a pivotal ...
tbsnews6 天
Three more firms downgraded to Z category over dividend failures, total reaches 94
On Monday, Kay & Que (Bangladesh), a publicly listed company, was also downgraded to the Z category for the same reason.